An EpiDoc ontological perspective: the epigraphs of the Castello Ursino Civic Museum of Catania via CIDOC CRM

The rich epigraphic heritage of the Castello Ursino Civic Museum of Catania has been studied by the EpiCUM project that encoded it in EpiDoc TEI XML, an XML based standard digital representation for cultural heritage contents. The project made the epigraphic heritage available in a digital museum: under the guise of the ‘Voci di Pietra’ exhibition, a selection of epigraphs were presented, implementing innovative presentation modalities thanks to a smart use of technological and digital means. Information contained in the epigraphs was semantically reorganized in a unique homogeneous container, the EpiONT ontology, constructed according to the Linked Open Data paradigm and to consolidated international standards. The encoding of the ancient texts, by the TEI standard and its EpiDoc subset, is wedded to the paradigmatic semantic web model for museums and cultural heritage. The EpiONT ontology is currently populated by 580 epigraphs collected in the Castello Ursino Civic Museum. Designed according to the CIDOC CRM standard, it makes use of the SKOS vocabularies of the EAGLE project concerning material, execution technique, type of inscription, and type of support of an epigraph. The EpiONT ontology additionally can handle any uncertainty in the origin and place of discovery of the epigraphs

Probing neutrino properties with charged scalar lepton decays

Supersymmetry with bilinear R-parity violation provides a predictive framework for neutrino masses and mixings in agreement with current neutrino oscillation data. The model leads to striking signals at future colliders through the R-parity violating decays of the lightest supersymmetric particle. Here we study charged scalar lepton decays and demonstrate that if the scalar tau is the LSP (i) it will decay within the detector, despite the smallness of the neutrino masses, (ii) the relative ratio of branching ratios Br({tilde tau}_1 --> e sum nu_i)/ Br({tilde tau}_1 --> mu sum nu_i) is predicted from the measured solar neutrino angle, and (iii) scalar muon and scalar electron decays will allow to test the consistency of the model. Thus, bilinear R-parity breaking SUSY will be testable at future colliders also in the case where the LSP is not the neutralino.Comment: 24 pages, 8 ps figs Report-no.: IFIC/02-33 and ZU-TH 11/0

Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort

Objectives Tocilizumab showed trends for improving skin fibrosis and prevented progression of lung fibrosis in systemic sclerosis (SSc) in randomised controlled clinical trials. We aimed to assess safety and effectiveness of tocilizumab in a real-life setting using the European Scleroderma Trial and Research (EUSTAR) database. Methods Patients with SSc fulfilling the American College of Rheumatology (ACR)/EULAR 2013 classification criteria, with baseline and follow-up visits at 12±3 months, receiving tocilizumab or standard of care as the control group, were selected. Propensity score matching was applied. Primary endpoints were the modified Rodnan skin score (mRSS) and FVC at 12±3 months compared between the groups. Secondary endpoints were the percentage of progressive/regressive patients for skin and lung at 12±3 months. Results Ninety-three patients with SSc treated with tocilizumab and 3180 patients with SSc with standard of care fulfilled the inclusion criteria. Comparison between groups did not show significant differences, but favoured tocilizumab across all predefined primary and secondary endpoints: mRSS was lower in the tocilizumab group (difference −1.0, 95% CI −3.7 to 1.8, p=0.48). Similarly, FVC % predicted was higher in the tocilizumab group (difference 1.5 (−6.1 to 9.1), p=0.70). The percentage of progressive/regressive patients favoured tocilizumab over controls. These results were robust regarding the sensitivity analyses. Safety analysis confirmed previously reported adverse event profiles. Conclusion Although this large, observational, controlled, real-life EUSTAR study did not show significant effectiveness of tocilizumab on skin and lung fibrosis, the consistency of direction of all predefined endpoints generates hypothesis for potential effectiveness in a broader SSc population

Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model

Objective To develop and validate the prognostic prediction model DU-VASC to assist the clinicians in decision-making regarding the use of platelet inhibitors (PIs) for the management of digital ulcers in patients with systemic sclerosis. Secondly, to assess the incremental value of PIs as predictor. Methods We analysed patient data from the European Scleroderma Trials and Research group registry (one time point assessed). Three sets of derivation/validation cohorts were obtained from the original cohort. Using logistic regression, we developed a model for prediction of digital ulcers (DUs). C-Statistics and calibration plots were calculated to evaluate the prediction performance. Variable importance plots and the decrease in C-statistics were used to address the importance of the predictors. Results Of 3710 patients in the original cohort, 487 had DUs and 90 were exposed to PIs. For the DU-VASC model, which includes 27 predictors, we observed good calibration and discrimination in all cohorts (C-statistic = 81.1% [95% CI: 78.9%, 83.4%] for the derivation and 82.3% [95% CI: 779.3%, 85.3%] for the independent temporal validation cohort). Exposure to PIs was associated with absence of DUs and was the most important therapeutic predictor. Further important factors associated with absence of DUs were lower modified Rodnan skin score, anti-Scl-70 negativity and normal CRP. Conversely, the exposure to phosphodiesterase-5 inhibitor, prostacyclin analogues or endothelin receptor antagonists seemed to be associated with the occurrence of DUs. Nonetheless, previous DUs remains the most impactful predictor of DUs. Conclusion The DU-VASC model, with good calibration and discrimination ability, revealed that PI treatment was the most important therapy-related predictor associated with reduced DU occurrence